Biogen Inc (NASDAQ:BIIB) EVP Alfred Sandrock sold 1,294 shares of Biogen stock in a transaction that occurred on Thursday, February 15th. The shares were sold at an average price of $298.85, for a total value of $386,711.90. Following the completion of the transaction, the executive vice president now owns 7,296 shares in the company, valued at $2,180,409.60. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink.
Biogen Inc (BIIB) opened at $287.45 on Wednesday. The stock has a market capitalization of $61,748.80, a price-to-earnings ratio of 24.11, a P/E/G ratio of 1.52 and a beta of 0.75. Biogen Inc has a 1-year low of $244.28 and a 1-year high of $370.57. The company has a current ratio of 2.34, a quick ratio of 2.07 and a debt-to-equity ratio of 0.47.
Biogen (NASDAQ:BIIB) last issued its quarterly earnings data on Thursday, January 25th. The biotechnology company reported $5.26 earnings per share (EPS) for the quarter, missing the consensus estimate of $5.44 by ($0.18). The firm had revenue of $3.31 billion for the quarter, compared to analyst estimates of $3.08 billion. Biogen had a return on equity of 38.32% and a net margin of 20.69%. The business’s revenue for the quarter was up 15.1% compared to the same quarter last year. During the same period in the prior year, the firm posted $5.04 earnings per share. analysts predict that Biogen Inc will post 24.88 EPS for the current year.
BIIB has been the topic of several analyst reports. Piper Jaffray Companies reiterated a “buy” rating and issued a $390.00 target price on shares of Biogen in a research note on Monday, December 18th. Nomura lifted their target price on Biogen from $355.00 to $420.00 and gave the company a “buy” rating in a research note on Friday, December 22nd. Royal Bank of Canada reiterated a “hold” rating and issued a $321.00 target price on shares of Biogen in a research note on Tuesday, December 5th. SunTrust Banks reiterated a “buy” rating and issued a $354.00 target price on shares of Biogen in a research note on Tuesday, October 24th. Finally, Canaccord Genuity initiated coverage on Biogen in a research note on Friday, October 27th. They issued a “hold” rating and a $340.00 target price on the stock. Ten equities research analysts have rated the stock with a hold rating and twenty-three have issued a buy rating to the stock. The company has an average rating of “Buy” and an average price target of $368.99.
TRADEMARK VIOLATION NOTICE: This piece was originally published by StockNewsTimes and is the sole property of of StockNewsTimes. If you are accessing this piece on another publication, it was illegally stolen and republished in violation of U.S. & international copyright & trademark legislation. The correct version of this piece can be viewed at https://stocknewstimes.com/2018/02/21/alfred-sandrock-sells-1294-shares-of-biogen-inc-biib-stock.html.
Biogen Inc is a biopharmaceutical company. The Company focuses on discovering, developing, manufacturing and delivering therapies to people living with serious neurological, rare and autoimmune diseases. The Company markets products, including TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA and FAMPYRA for multiple sclerosis (MS), FUMADERM for the treatment of severe plaque psoriasis and SPINRAZA for the treatment of spinal muscular atrophy (SMA).
Receive News & Ratings for Biogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biogen and related companies with MarketBeat.com's FREE daily email newsletter.